Cancer vaccines are not one product, one treatment stage or a universal preventive injection. Some aim to prevent infections that can lead to cancer; treatment vaccines try to generate an immune response relevant to a person’s cancer. The distinction changes what a result means and who it could concern. 1 2
This guide follows selected treatment-vaccine programs. It is not a complete cancer-therapy pipeline or an assessment of what an individual should receive. The latest source check for this edition is September 17, 2026.
The two developments to separate
For melanoma, Merck and Moderna announced positive Phase 3 INTerpath-001 topline results on August 19, 2026 for intismeran autogene plus pembrolizumab after complete surgical removal. The announcement is a development milestone, not a published full results table or marketing authorization. 3
For pancreatic cancer, an April 2026 MSK conference account extended observation of a small earlier autogene-cevumeran cohort. It did not report a new randomized comparison of vaccine versus no vaccine. 4
The useful question is not which headline sounds bigger. It is what uncertainty each study can reduce: a randomized combination comparison and long-term immune-response follow-up have different jobs.
Find the answer by program, not by the word “vaccine”
| Subject | What this edition provides | Essential distinction |
|---|---|---|
| Melanoma: intismeran, V940, mRNA-4157 | 2026 Phase 3 status and interpretation | Same program names; do not attach earlier percentages to a later trial |
| Melanoma: KEYNOTE-942 | The original Phase 2b result | A defined historical analysis, not the whole current evidence record |
| Pancreatic cancer: autogene cevumeran | What happened after the first report | Longer observation of the same people is not an independent cohort |
| Prevention and established treatment examples | Cancer-vaccine types | Preventing infection differs from treating an existing malignancy |
| Selecting tumor-specific targets | Personalized cancer vaccines | Individualization describes design, not guaranteed effectiveness |
These links lead to evidence explanations, not treatment vendors or paid enrollment services.
Why the cancer stage belongs in the headline
An adjuvant study treats people after the main treatment, such as surgery, with the aim of reducing later disease events. That is different from demonstrating that a vaccine shrinks widespread measurable cancer. The INTerpath-001 announcement concerns a postsurgical setting. 3
Consequently, “the tumor disappeared” would be an inappropriate summary of that study’s stated question. A useful account identifies the surgical context before describing recurrence outcomes.
Similarly, a result in a named melanoma population cannot become a forecast for pancreatic cancer merely because both approaches use RNA. Treat each combination, population and clinical endpoint as its own evidence record.
Immune activity is not the final clinical answer
A vaccine may generate a measurable tumor-directed immune response. That observation helps establish whether the intended biological process occurred. It does not, by itself, quantify how much longer participants live or how their quality of life changes. NCI distinguishes treatment-vaccine mechanisms and their intended clinical purposes. 1
Our reporting therefore keeps biological findings, recurrence measures, overall survival and adverse effects in separate sections. A favorable result in one column does not fill the others automatically.
The comparison with CAR-T and checkpoint inhibitors explains why combining immune approaches may be studied without making them interchangeable.
Are cancer vaccines available?
Some specific treatment products already have defined authorizations. For example, FDA’s Provenge record names a limited prostate-cancer indication. That is not authorization for the individualized RNA programs discussed above or for treating every prostate cancer. 5
For an investigational program, an article is not an access route. Our clinical-trial guide links official records and explains the difference between a listed study, a recruiting site and an eligibility decision. No price for investigational intismeran or autogene cevumeran is established by the evidence reviewed here.
What would change this guide next?
For the melanoma program, the most useful additions would be the complete Phase 3 efficacy and safety results, followed by an actual regulatory decision if one occurs. For pancreatic research, a controlled comparison would address a different and more decisive clinical question than another update of the same responder groups.
This is the organizing rule for this page: follow the next evidence that changes the answer, rather than collecting another version of the same announcement. The dated reports retain their original result periods so that a newly updated guide does not disguise old findings as new discoveries.